Myocarditis following mRNA COVID-19 vaccination has recently been reported to health
authorities in the United States and other countries. Cases predominately occur in young …

Background Clinical trials of the BNT162b2 vaccine, revealed efficacy and safety. We report
six cases of myocarditis, which occurred shortly after BNT162b2 vaccination. Methods …

We report three patients who presented with chest pain after receiving either the BNT162b2
Pfizer/BioNTech or mRNA-1273 Moderna/NIH vaccine. Clinical presentation, biomarker, and …

Background and objectives According to some reports, there is a link between the
development of myocarditis and the administration of messenger RNA (mRNA) vaccines …

Introduction The etiology of myocarditis often remains undetermined. A large variety of
infectious agents, systemic diseases, drugs, and toxins can cause the disease. We report the …

Importance Myocarditis has been reported with COVID-19 but is not clearly recognized as a
possible adverse event following COVID-19 vaccination. Objective To describe myocarditis …

Myopericarditis following mRNA Covid-19 vaccination has recently been reported to health
authorities in a lot of countries. They can occur in very rare cases after either the Moderna …

Acute myocarditis following mRNA COVID‐19 vaccination was reported by the European
Medicine Agency safety committee as a rare adverse event. We present a case series of …

Myocarditis after Covid-19 Vaccination Two patients who had received Covid-19 mRNA
vaccination are described. One received the BNT162b2 vaccine; the other received the …

Importance The BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine was
authorized on May 10, 2021, for emergency use in children aged 12 years and older. Initial …